AIDP’s patented prebiotic ingredients, PreticX and Actazin (a green kiwi extract powder) were studied together in a recent double blind placebo controlled clinical trial. 240 Healthy participants were randomized into three groups – one group received a placebo, one group received a daily dose of 600 mg Actazin, while the third group received a 600 mg dose of Actazin, as well as a 1.4 gram dose of 70% PreticX, over the course of the 28-day study.
Stool samples were evaluated for Bristol Stool Scale (BSS) scores at the beginning of the study, as well as at day 28 of the study. The BSS is a diagnostic scale which classifies stool forms into seven types which range from constipated through normal, to diarrhea. Actazin, in combination with PreticX gave significantly improved scores over all other products and the placebo, demonstrating digestive improvements in all of the participants.
PreticX was the subject of interest in the trial due to its capacity to boost levels of beneficial bacteria in the gut. AIDP reports that it is effective at low doses with minimal side effects often associated with traditional fibers. Actazin, which has also been involved in a body of clinical research, is suggested to have a synergistic relationship with PreticX.
“The patent is a great addition to AIDP’s prebiotic portfolio,” Dr. Jennifer Gu, vice president of Research and Development, said. “Our research focuses on providing proven results to our customers. Securing this patent ensures our customers have a verified unique product for daily digestive support.”